Tepnel Appointed Preferred Supplier to AstraZeneca for DNA Extraction Services
News May 04, 2006
Under the terms of this agreement Tepnel has been appointed as a preferred supplier to AstraZeneca for DNA extraction services.
By continuing to provide a high quality service in the market Tepnel will have the opportunity to compete for further business and AstraZeneca will benefit from volume-related discounts.
Ben Matzilevich, CEO, commented, "Following our recent positive preliminary financial results for 2005 we are delighted at being able to announce more good news."
"AstraZeneca is already a valued client that has been working with us for a number of years and this agreement is proof of the high level of client service and technical expertise that we are able to deliver."
"This agreement further strengthens Tepnel’s position in the pharmaceutical industry as one of Europe’s largest providers of DNA extraction services."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.